About CLINUVEL

"Focus really pays off in the end"

25 Feb 2012

Following CLINUVEL's landmark filing of a marketing authorisation application for the drug SCENESSE® (afamelanotide) with the European Medicines Agency, CEO Dr Philippe Wolgen discusses the challenges to date and what may lie ahead for CLINUVEL.

Quick Links